Understanding how NELFE affects MYC signaling in liver cancer
Official title: Deciphering the role of NELFE in modulating MYC signaling in HCC
Funded at Thomas Jefferson University · NIH-10885209 · Data updated 2026-11-12
This study is looking at a protein called NELFE to see how it affects liver cancer, hoping to find new ways to treat this type of cancer by better understanding how it grows.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | July 10, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $337,674 |
| NIH project number | 5R01CA284017-02 |
| Project ID | NIH-10885209 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with hepatocellular carcinoma, particularly those from populations with higher incidence rates such as Hispanics, Blacks, and Asian Pacific Islanders.
✕Less likely to help
Patients with liver cancer that is not driven by MYC signaling or those with other types of cancer may not benefit from this research.
What this research studies
This research investigates the role of a protein called NELFE in liver cancer, specifically hepatocellular carcinoma (HCC). The study aims to understand how NELFE influences MYC signaling, which is often deregulated in HCC, leading to aggressive tumor growth. By examining the molecular mechanisms involved, the researchers hope to identify new therapeutic strategies that could indirectly target MYC, which is currently considered an undruggable target. Patients may benefit from insights that could lead to more effective treatments for HCC.
Why it matters
Potential benefit: If successful, this research could lead to new therapies for liver cancer that improve patient outcomes.
How similar studies have gone: While the approach of targeting MYC indirectly through NELFE is innovative, similar research has shown promise in understanding cancer signaling pathways, suggesting potential for success.
Where this research is happening
-
Thomas Jefferson University
Philadelphia, United States Active
Researchers
- Principal investigator: Dang, Hien T. — Thomas Jefferson University
- Study coordinator: Dang, Hien T.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.